First in China: CAR-T Therapy Price Slashed by Over 1 Million Yuan to 200,000 Yuan

Five years ago, when the first CAR-T cell therapy hit the Chinese market at 1.2 million yuan (approximately $165,000 USD) per dose, it went viral for all the wrong reasons. "One injection, sell one apartment," became the grim shorthand for a treatment that promised to cure certain blood cancers but priced itself beyond the reach of nearly every patient in the country.

Now, a Chinese biotech company is proposing something that would have seemed impossible just a few years ago: a CAR-T therapy priced at roughly 200,000 yuan (approximately $27,500 USD) — a price cut of more than 1 million yuan from the current market range.

The question is whether Huadao (Shanghai) Biopharma Co., Ltd. can actually deliver on that promise, or whether the entire CAR-T industry has reached a genuine inflection point in its long quest to bring these therapies to mass markets.

Why CAR-T Costs a Fortune

To understand the price, you have to understand the process. CAR-T therapy is not a pill that comes off an assembly line. It begins with extracting T cells from a patient's own blood, shipping them to a specialized laboratory, where scientists activate the cells, insert a chimeric antigen receptor (CAR) gene using a lentiviral vector, and grow the modified cells until they reach a therapeutic dose. The finished product is then frozen, quality-checked, shipped back to the hospital, and reinfused into the patient after a lymphodepleting chemotherapy regimen.

Every single dose is a one-of-one custom manufacturing job. There are no economies of scale in the traditional sense — each patient corresponds to an independent production batch.

Then there is the matter of raw material quality. T cells from patients who have undergone multiple rounds of prior treatment may already be aged or have diminished proliferative capacity, raising the risk of manufacturing failure. Add in the costs of blood collection, cold-chain logistics, centralized production, and return shipping, and the expenses compound at every step.

The viral vector alone accounts for approximately 26% of the total product cost. It must be manufactured under current Good Manufacturing Practice (cGMP) conditions, with each step — from cell transfection to purification, concentration, and safety testing — requiring expensive equipment, reagents, and consumables.

On top of that, the R&D bill is staggering. Research estimates suggest that bringing a single oncology cell therapy from target identification to market approval costs approximately $500 million to $600 million USD and takes more than 10 years, with pharmaceutical companies absorbing the sunk costs of numerous failed pipeline candidates along the way.

The result: per-case product costs frequently exceed $350,000 USD and can reach more than $500,000 USD. With limited patient volumes after launch, companies have had no choice but to price high enough to recover their investment.

The Global Price Tag

In the United States, the FDA has approved seven autologous CAR-T products. Their wholesale acquisition costs range from the low $300,000s to the low $500,000s USD. When the full cost of treatment is tallied — hospitalization, monitoring, managing side effects — the total bill for a single patient typically lands between $500,000 and $1 million USD or more.

In China, two CAR-T products have been on the market. One is priced at 990,000 yuan (approximately $136,000 USD), the other at 1.29 million yuan (approximately $177,000 USD). The 300,000-yuan gap between them did little to change the fundamental reality: neither was within reach of ordinary patients.

Huadao's Gamble

On April 30, the Center for Drug Evaluation (CDE) under China's National Medical Products Administration formally accepted Huadao Biopharma's filing for its lead drug, Wanji'aoluncai injection (万基奥仑赛注射液), for the treatment of refractory or relapsed non-Hodgkin lymphoma.

Simultaneously, the company signaled that upon market approval, it would price the therapy at just over 200,000 yuan (approximately $27,500 USD) — shattering the existing 990,000-to-1.29-million-yuan price band for approved CAR-T products in China.

Yu Xuejun, chairman and general manager of Huadao Biopharma, told media that the root cause of high costs in the cell therapy field lies in the industry's end-to-end dependence on imported technology and equipment.

In June 2023, Huadao's full production chain passed a technical review by the CDE. The company calls its proprietary system the "Ant Workshop" — a fully unmanned, automated, closed-cell drug manufacturing platform.

According to Yu, the system reduces manufacturing costs to approximately one-tenth of imported equivalents while boosting production capacity to more than 50 times that of traditional methods. It has also lifted the cell production success rate from roughly 80% to 99%.

The company's Phase 2 production base, currently under construction, is designed for an annual capacity of 9,000 doses — significantly higher than the existing capacity levels of currently marketed CAR-T products in China.

In essence, Huadao is attempting to transform CAR-T from a highly import-dependent, labor-intensive "bespoke" manufacturing model into a domestically sourced, automated, and scaled production system — attacking the cost problem from the manufacturing end.

Three Axes for Cutting Costs

Huadao's price play is not an isolated case. Globally, the playbook for bringing down CAR-T costs is crystallizing around three main strategies.

The first is localized production of autologous CAR-T. India's ImmunoAct has priced its NexCAR19 at $30,000 to $40,000 USD (approximately 210,000 to 290,000 yuan) — roughly one-tenth the price of Western equivalents. The company developed its own lentiviral vector, cutting vector costs to one-fifth of U.S. levels, and benefits from lower labor costs. In a Phase I/II study of 64 patients, NexCAR19 demonstrated an overall response rate (ORR) of 73%, with a complete response (CR) rate of 73% in B-ALL patients — all of whom were minimal residual disease (MRD) negative. The first patient's total treatment cost was 4.2 million Indian rupees, approximately 350,000 yuan.

The second strategy is universal, or "off-the-shelf," CAR-T. Instead of using each patient's own cells, this approach uses T cells from healthy donors to create batch-producible therapies. Theoretically, costs could drop to one-fifth or even one-tenth of autologous CAR-T. The challenge: preventing graft-versus-host disease and immune rejection. No universal CAR-T product has been approved anywhere in the world, but Chinese companies including CARsgen (科济药业) have entered clinical-stage development.

The third and most aggressive approach is in vivo CAR-T — skipping the cell extraction step entirely and injecting vectors directly into the patient's body to generate CAR-T cells internally. The major pharmaceutical players are placing enormous bets: AbbVie acquired Capstan for $2.1 billion USD to pursue LNP-mRNA-based in vivo CAR-T; AstraZeneca acquired EsoBiotec for $1 billion USD for the ESOT-01 platform; and Eli Lilly acquired Kelonia for $7 billion USD for the iGPS platform. Chinese companies including JiYin Bio and Easymofeng have also invested in related platforms.

In theory, in vivo CAR-T could push costs below one-tenth of traditional CAR-T. If this approach truly works, prices under 100,000 yuan are not entirely out of the question.

The Payment Problem

But even if manufacturing costs come down, getting patients access to these therapies requires solving a separate problem: who pays.

Japan offers one model. Patients there can access the CAR-T therapy Kymriah for approximately 20,000 yuan — not because the manufacturer slashed the price, but because Japan's insurance system caps patient out-of-pocket costs. France uses a tiered discount and risk-sharing agreement: the public price of Kymriah is 300,000 to 400,000 EUR, with national insurance covering 65%, hospital supplementary insurance covering 25%, and patients paying roughly 10%.

In the United States, Novartis and Gilead have both signed pay-for-performance agreements with insurers — if the drug doesn't produce a response, fees are reduced or waived. In China, Fosun Kite's Yescarta (阿基仑赛) has piloted a similar model.

China's own multi-tier payment system is gradually taking shape. Shanghai's Huiminbao commercial insurance program has included CAR-T therapies for four consecutive years, with cumulative payouts exceeding 40 million yuan over three years, benefiting more than 80 patients. Nationwide, over 100 local "Huiminbao" programs have incorporated CAR-T drugs into their specialty medication catalogs, with reimbursement ratios of 30% to 50%.

At the national level, a "medical insurance + commercial insurance + Huiminbao + patient assistance" model exists, but CAR-T has never broken through the widely recognized threshold of 300,000 yuan in annual treatment costs. After four consecutive years of unsuccessful bids to enter the national medical insurance catalog, CAR-T did gain entry into the commercial insurance innovative drug catalog — an important step forward.

But if the price truly drops to just over 200,000 yuan, the calculus changes entirely. Below the 300,000-yuan threshold, the existing multi-tier payment architecture could actually begin to work for patients rather than against them.

The question is no longer just whether CAR-T can be made cheaper. It is whether the ecosystem of pricing, insurance, and patient support can evolve fast enough to match the science.